Vivos Therapeutics (VVOS)
NASDAQ:VVOS
Want to see VVOS full AI Analyst Report?
Top Page
Vivos Therapeutics
(NASDAQ:VVOS)
Select Model
Select Model
Rating:44Neutral
Price Target:
$0.65
▼(-70.72% Downside)
Action:Reiterated
Date:05/21/26
The score is held down primarily by weak financial performance (deep losses, significant cash burn, and negative equity) and bearish technicals (below major moving averages with negative MACD). Earnings-call momentum and improving gross margin provide some support, but near-term funding and profitability execution risks remain the key overhang.
Positive Factors
Strong revenue growth and rising patient volumes
Sustained double-digit revenue growth and a 72% jump in completed appointments indicate durable demand and improving adoption of Vivos’ care pathway. Higher visit volumes suggest repeatable provider throughput gains that can translate into steady top-line growth as provider networks scale.
Negative Factors
Negative equity and meaningful outstanding debt
A negative equity position and ~$11.9M of debt materially reduce financial flexibility and raise refinancing and covenant risk. This structural weakness limits the company’s ability to invest, makes external financing more dilutive or costly, and heightens long-term solvency concerns.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong revenue growth and rising patient volumes
Sustained double-digit revenue growth and a 72% jump in completed appointments indicate durable demand and improving adoption of Vivos’ care pathway. Higher visit volumes suggest repeatable provider throughput gains that can translate into steady top-line growth as provider networks scale.
Read all positive factors
Vivos Therapeutics (VVOS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$9.31M
Dividend YieldN/A
Average Volume (3M)421.86K
Price to Earnings (P/E)―
Beta (1Y)1.08
Revenue Growth33.77%
EPS Growth-20.22%
CountryUS
Employees109
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-2.30
Shares Outstanding13,894,600
10 Day Avg. Volume324,525
30 Day Avg. Volume421,860
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)-14.00
Price to Sales (P/S)1.20
P/FCF Ratio-1.18
Enterprise Value/Market Cap1.53
Enterprise Value/Revenue0.73
Enterprise Value/Gross Profit1.18
Enterprise Value/Ebitda-0.68
Forecast
1Y Price Target
$2.42Price Target Upside8.86% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.15
Revenue Forecast (FY)$23.27M
Vivos Therapeutics Business Overview & Revenue Model
Company Description
Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers the Vivos System, a non-invasiv...
How the Company Makes Money
Vivos Therapeutics generates revenue primarily by selling and supporting its sleep apnea treatment and diagnostic ecosystem. Key revenue streams include: (1) sales of oral appliance/therapeutic devices and related components used in its OSA treatm...
Vivos Therapeutics Earnings Call Summary
Earnings Call Date:May 20, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Aug 19, 2026
Earnings Call Sentiment Neutral
The call highlighted very strong top-line momentum—70% year-over-year revenue growth, 34% sequential growth, a 10 percentage-point gross margin improvement and rapidly rising patient volumes and KPIs driven by the SCN acquisition and provider productivity gains. However, these operational gains were offset by substantial increases in G&A and cash burn, a low cash balance (~$2.1M), increased discounts reducing product revenue, and an explicit need for additional financing and debt restructuring. Management presented multiple high-margin initiatives (pediatrics, insomnia services, medical affiliations) that could materially improve profitability, but near-term execution and capital availability remain material risks.Positive Updates
Strong Revenue Growth (YoY and QoQ)
Total revenue increased to $5.1 million in Q1 2026, a rise of approximately $2.1 million or ~70% year-over-year versus $3.0 million in Q1 2025, and a 34% increase compared to Q4 2025.
Negative Updates
Sharp Rise in General & Administrative Expenses
G&A expenses increased by $4.1 million to $9.0 million in Q1 2026 versus $4.9 million in Q1 2025 (an increase of ~84%), driven primarily by SCN operating costs (~$1.5M), additional treatment center salaries (~$1.5M), and $900,000 of nonrecurring professional fees.
Read all updates
Q1-2026 Updates
Positive
Negative
Strong Revenue Growth (YoY and QoQ)
Total revenue increased to $5.1 million in Q1 2026, a rise of approximately $2.1 million or ~70% year-over-year versus $3.0 million in Q1 2025, and a 34% increase compared to Q4 2025.
Read all positive updates
Company Guidance
The company guided that its pivot is already driving rapid top-line momentum and expects margin improvement through 2026, citing Q1 revenue of $5.1M (up ~$2.1M or 70% YoY and 34% QoQ), a 72% rise in completed patient appointments (2,438 to 4,186), myofunctional visits up 43% (337 to 481), and April’s highest-ever Visit 2s; it reported 5,304 appliance/positioner units sold for ~$1.4M (vs $1.8M prior year), gross profit of $3.1M (+103%), gross margin up 10 points to 60% (from 50%), cost of sales $2.1M (+38%), G&A $9M (+$4.1M), D&A ~$500k, net cash used in operations ~$6M, cash $2.1M and liabilities ~$26.3M as of March 31; looking ahead management expects practice-level net contribution margins approaching 50%+ by year-end, pediatric program net margins >60% with potential site revenue ~ $1M/year (revenue from pediatric program to begin in July), insomnia services to add $2–3k per patient in year one, deferred VIP revenue of ~ $100k to be recognized by year-end, capacity expansions (Henderson doubling production capacity in June), and the need for additional financing and senior-debt restructuring to support growth.Vivos Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
12
Very Negative
Cash Flow
14
Very Negative
| Breakdown | Mar 2026 | Mar 2025 | Dec 2023 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 17.44M | 15.03M | 13.80M | 16.02M | 16.89M |
| Gross Profit | 10.54M | 9.02M | 8.27M | 10.02M | 12.60M |
| EBITDA | -18.59M | -10.59M | -16.68M | -24.36M | -19.54M |
| Net Income | -21.23M | -11.14M | -13.58M | -23.84M | -20.29M |
Balance Sheet | |||||
| Total Assets | 25.15M | 15.28M | 10.73M | 13.72M | 33.69M |
| Cash, Cash Equivalents and Short-Term Investments | 2.03M | 6.26M | 1.64M | 3.52M | 24.03M |
| Total Debt | 13.50M | 1.51M | 2.00M | 2.41M | 1.63M |
| Total Liabilities | 26.70M | 7.33M | 10.32M | 8.92M | 8.15M |
| Stockholders Equity | -1.49M | 7.95M | 411.00K | 4.80M | 25.54M |
Cash Flow | |||||
| Free Cash Flow | -17.60M | -13.26M | -12.75M | -20.51M | -18.13M |
| Operating Cash Flow | -15.26M | -12.69M | -11.95M | -19.59M | -15.73M |
| Investing Cash Flow | -7.53M | -568.00K | -853.00K | -924.00K | -2.61M |
| Financing Cash Flow | 18.56M | 17.88M | 10.92M | 0.00 | 24.17M |
Vivos Therapeutics Technical Analysis
Neutral
2.22
Price Trends
0.94
Negative
1.29
Negative
2.13
Negative
Market Momentum
-0.08
Negative
43.86
Neutral
63.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VVOS, the sentiment is Neutral. The current price of 2.22 is above the 20-day moving average (MA) of 0.67, above the 50-day MA of 0.94, and above the 200-day MA of 2.13, indicating a neutral trend. The MACD of -0.08 indicates Negative momentum. The RSI at 43.86 is Neutral, neither overbought nor oversold. The STOCH value of 63.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for VVOS.
Vivos Therapeutics Risk Analysis
Vivos Therapeutics disclosed 85 risk factors in its most recent earnings report. Vivos Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 2 New Risks
1.
The failure to expand our market penetration with DME distribution agreements would adversely affect our revenue and results of operations. Q4, 2023
2.
We face risks from negative publicity from unregistered oral appliances which has and may continue to hurt our sales. Q4, 2023
Vivos Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $40.31M | -0.40 | -164.92% | ― | -9.46% | 18.03% | |
47 Neutral | $54.05M | -2.10 | 239.44% | ― | 10.38% | 20.70% | |
45 Neutral | $17.93M | -5.55 | -148.64% | ― | 7.73% | 55.39% | |
45 Neutral | $16.11M | -0.66 | -312.04% | ― | -100.00% | 100.00% | |
44 Neutral | $9.31M | -0.41 | -335.47% | ― | 33.77% | -20.22% |
* Healthcare Sector Average
VVOS
Vivos Therapeutics
0.70
-1.70
-70.83%
IRIX
Iridex
1.05
0.05
5.00%
CODX
Co-Diagnostics
8.53
0.69
8.86%
ADGM
Adagio Medical Holdings
0.72
-0.41
-35.93%
COCH
Envoy Medical
0.71
-0.80
-53.00%
NXL
Nexalin Technology, Inc.
0.61
-0.61
-50.00%
Vivos Therapeutics Corporate Events
Delistings and Listing ChangesPrivate Placements and FinancingRegulatory Filings and Compliance
Vivos Therapeutics Faces Nasdaq Listing Compliance Challenges
Negative
Apr 22, 2026
On April 17, 2026, Vivos Therapeutics, Inc. disclosed that Nasdaq had notified the company its stockholders’ equity, which was approximately negative $1.55 million as of December 31, 2025, fell below the $2.5 million minimum required for con...
Business Operations and StrategyPrivate Placements and Financing
Vivos Therapeutics Completes Private Placement to Bolster Liquidity
Positive
Apr 3, 2026
On March 31, 2026, Vivos Therapeutics, Inc. completed a private placement with V-Co Investors 3 LLC, an affiliate of existing sponsor New Seneca Partners, selling common stock, a pre-funded warrant and Series A and B common stock purchase warrants...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.